Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: 1. Histologically confirmed locally advanced resectable colon adenocarcinoma (colon cancer located more than 12 cm from the anal verge); 2. Imaging staging is T4, or T3 (with invasion of the muscularis propria ≥5 mm) combined with at least one of the following risk factors: number of metastatic lymph nodes ≥1, extramural vascular invasion (EMVI+), involvement of the mesocolic fascia. (TNM clinical staging (cTNN) according to the 8th edition of AJCC/UICC guidelines); 3. No distant metastasis; 4. At least one measurable lesion ; 5. Immunohistochemical testing of endoscopic biopsy samples by the study center's pathology department confirms diagnosis as pMMR, or genetic testing confirms MSS/MSS-L status (by PCR or NGS method); 6. No prior anti-tumor treatment for colorectal cancer; 7. Age ≥18 years and ≤75 years, regardless of gender; 8. ECOG performance status score 0-1; 9. Signed written informed consent before enrollment; 10. Expected survival of more than 12 weeks;…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source